The article is called
"Synthetic Biologics: A Developer Of New Biologics Focused On Serious Infections" Just look it up. It is from LifeScienceLeaderdotcom.
By Wayne Koberstein, executive editor
Yeah, really, really good.
I bought at .55 the other day and sold most of it today...not too bright on my part.
But, I believe it just may dip a bit on Monday.
actually have a minute amount of estriol.
The premise behind SYNs study is that they believe that it is the very small amount of estriol in birth control pills that is helping patients with MS (preventing relapses).
Also it is important to note that previous studies have indicated that estriol may be neuro-protective...if this is the case along with improved cognition, this could be Major News and then SYN will get the exposure it deserves. As Riley says "We may remain undervalued until we see results" (paraphrasing). Well, these results are quickly approaching!
I am actually amazed at this price...if results are good they cannot be ignored and I expect this price to increase.
Usually prior to a significant catalyst there are a bunch of newbies that will enter the picture. It hasn't occurred this far. This company needs some more exposure because it is still in stealth mode here.
Is the market NOT perceiving this as I do? (as a significant catalyst)
Will we get some Exposure on Monday?
I have the llink in my notes...when I get home I will post it.
It was an interview. My memory is so horrible if I don't have it written right in front of me then chances are I will totally forget. Can't even remember who it was and just read it again a few hours ago.
Should of posted the link.
Yeah....this happens frequently, never know what price it actually is, maybe it is different depending on brokerages.
Dang right they should correlate...exactly the same.
Looks like your volume was a nice chunk of today.
Not impressed with the volume whatsoever today.
Should of put more into ONCS yesterday on Tuesday.
Did we acquire worldwide rights to the SYN-004 from Ipsat Therapeutics?
Just looking over some notes and have an article titled: Orally administered b-lactamase enzymes represent a novel strategy to prevent colonization by Clostridium difﬁcile.
It is is published in the Journal of Antimicrobial Chemotherapy and discusses a trial back in 2007, for that particular beta lactamase enzymes.
Just wondering if this is who we acquired rights from??
Although the repurposing and new investment have pulled the company out of the nano-cap depths, going Syn has gone from a $15 million to a $156 million market cap in the past two years. CEO Jeff Riley says he believes it will remain significantly undervalued until it achieves visible results. Is this is hint?
“If we were private and we did an IPO today, we would be about a $350 million market cap, because we would have the visibility, and people would value us accordingly. Companies with recent IPOs are probably more accurately valued than a company like ours that has started over from zero. But if I were an investor, I would go with a company like ours because there’s a builtin positive upside — our experience and skills in addition to the real assets we’ve built.”
Is that also a hint?
IDK...but I know confidence when I see it. I don't believe that Riley knew anything about the results when he said this last month.
You are evaluating CTIX with a Discounted Cash flow analysis?
As soon as Aspire is done selling their Round 1 Shares they the price will reflect-- in fact I think that they are still holding shares that they purchased over $2 and waiting to unload well over $2.50.
The first deal was on 12/10/2012 for a total of $10 million and the price around that time was 1.50 and Aspire really unloaded in the $2.20's for the first load of shares.
Look back at the volume increases in a 14 trading day period it went from 1.49 to $2.47 -- it was EASY Money back then because it was totally OBVIOUS with the Volume increases. That is not the case right now as volume has decreased as I believe CTIX wants the price to increase prior to making huge purchase orders which will save on dilution if that is what they are doing.
Just 3 years ago there were volume days of ZERO and some of my buys were the only ones...flat out the ONLY volume of the day.
Aspire will not allow this to FREE fall as they were still buying over $2 so they have not been able to sell all those shares over $2...I haven't done an analysis lately because my focus is elsewhere right now and just holding tight but I believe the bottom is near for CTIX.
I really believe with all the "Potentials" that this is still a good buy, but the market is saying show me the results and the quickest way to making a profit -- when good results are announced this should do well, but it is important to note the dilution with the issuance of new shares which will increase market with the same price and I don't believe the market is saying that they value CTIX much over $200 million at this time...wait for ACTUAL Results. That in my opinion will be what kick starts the heart of CTIX once again.
Is there a "No Shorting" Clause in the contract with Aspire?
Had to do some research on what you were referring to about the KP Kaiser Permanente.
Yeah Retro studies are like you said: Great, but there is so many variables to consider. Had to do these for Statistics in college and had to learn that there is a lot to consider.
Excerpt from Abstract mentioned by J Brantz
Estriol likely inhibits iNOS gene expression since the hormone blocks LPS induction of iNOS RNA levels. The pro-inflammatory cytokines IFN-gamma and TNF-alpha are believed to be important modulators of multiple sclerosis. Here, we demonstrate that estrogens and progesterone also inhibit NO production by microglial cells activated in response to these cytokines. Activated microglia elicit TNF-alpha in addition to NO and we further demonstrate that estrogens and progesterone repress TNF-alpha production by these cells. Finally, estriol and progesterone, at concentrations consistent with late pregnancy, inhibit NO and TNF-alpha production by activated microglia, suggesting that hormone inhibition of microglial cell activation may contribute to the decreased severity of multiple sclerosis symptoms commonly associated with pregnancy.
An answer to your question earlier: As I asked this directly to the company and received this response: The data WILL be released Concurrent to Dr. Voskuhl's presentation. So, it means that it will probably be released on that day for sure or minutes before the presentation because it is considered "Material Information" in which they need to make it publicly available...at least in abstract form.
You say it so much more Professionally.
Thank You very much for this post.
It is inconclusive until we know more.
The pill comes in 2 forms: combination pills and progestin-only pills.